Skip to content

Amidst the highs and lows of 2020, MiRXES managed to rise to the occasion and make our name on a global stage.

Armed with a wealth of experience from the pandemic, MiRXES is now set to return to its roots and focus on producing best-in-class multi-cancer early diagnostics.

As the world’s first molecular blood test for detecting gastric cancer, GASTROClear could play a pivotal role in stopping the deadly disease in its earliest stages.

By targeting nearly 400 miRNAs linked to over 20 different diseases with a single product, MiRXES’ ID3EAL PanoramiR microRNA knowledge panel proves that it’s possible to achieve more with less. 

Discover how MiRXES and its partners are developing early detection tests to fight the world’s leading cause of death: heart disease.  

From regulating genes to aiding disease diagnosis, microRNAs’ outsized impact certainly belies their tiny proportions.

Now a trusted name in biotechnology manufacturing, MiRXES is planning to boost its capabilities by tapping upon local talent and the defining technologies of Industry 4.0.

Founded with a focus on microRNA discoveries and diagnostics, MiRXES is now looking to solidify its manufacturing and delivery capabilities and help Singapore elevate its competitiveness on the global stage.

How did MiRXES scale up production of Singapore’s Fortitude COVID-19 test kit for the world? Find out in this infographic.

What are the landmarks in MiRXES’ journey towards becoming a leader in microRNA-centric discovery and diagnostics? Find out in this infographic.

How does the launch of Singapore Standard 656 (SS656) help to make microRNA-based diagnostics mainstream? Find out in this infographic.